Use of eIF-5A to kill multiple myeloma cells
The present invention relates to eucaryotic initiation factor 5A and the use of polynucleotides encoding the same to inhibit cancer cell growth and inhibit metastases. In a preferred embodiment, eIF-5A1 is used to kill multiple myeloma cells.
1 . A composition for killing myeloma cells comprising a polynucleotide encoding eIF5A.
2 . The composition of claim 1 wherein the eIF5A is selected from the group consisting of eIF5A1, eIF5A2 or a mutant eIF5A1.
3 . The composition of claim 2 wherein the eIF5A is eIFA1.
4 . The composition of claim 3 wherein the composition further comprises a delivery vehicle.
5 . The composition of claim 4 wherein the delivery vehicle is selected from the group consisting of a vector, plasmid, liposome, or dendrimer.
6 . The composition of claim 5 wherein the delivery vehicle is a vector.
7 . The composition of claim 6 wherein the delivery vehicle is an adenovirus vector.
8 . The composition of claim 5 wherein the delivery vehicle is a liposome.
9 . The composition of claim 5 wherein the delivery vehicle is a dendrimer.
10 . Use of eIFA to make a medicament to kill multiple myeloma cells in a subject having multiple myeloma.
11 . The use of eIF5A of claim 10 wherein the eIF5A is eIF5A1, eIF5A2, or a mutant eIF5A1 wherein the mutant eIF5A1 has had the conserved lysine changed to an alanine or any other amino acid, and wherein the mutant is unable to be hypusinated.
12 . A method of killing multiple myeloma cells, the method comprising administering to the myeloma cells a composition comprising a polynucleotide encoding eIF5A1, wherein the composition kills the multiple myeloma cells.
13 . The method of claim 12 wherein the eIF5A1 is a mutant, wherein said mutant has had the conserved lysine changed to an alanine or any another amino acid and wherein said mutant is unable to be hypusinated.
14 . The method of claim 12 wherein the composition comprises a vector.
15 . The method of claim 14 wherein the vector is an adenovirus vector.
16 . The method of claim 12 further comprising administering siRNA directed against eIF-5A1, wherein said siRNA down regulates endogenous expression of eIF-5A1, and wherein said down-regulation of expression of eIF-5A1 down regulates expression of IL-6 and wherein said down regulation of IL-6 kills multiple myeloma cells.
17 . A method of inducing apoptosis in multiple myeloma cells in a subject having multiple myeloma, said method comprising administering the composition of claim 3 , wherein the eIF5A1 in said composition induces apoptosis in the multiple myeloma cells.
18 . The method of claim 17 wherein the composition is administered intravenously.
19 . The method of claim 17 wherein the composition further comprises a liposome.
20 . The method of claim 17 wherein the composition further comprises a dendrimer.
21 . A method of killing multiple myeloma cells comprising administering the composition of claim 3 and further administering a conventional multiple myeloma therapy.